GlaxoSmithKline launched a $50 million strategic venture capital fund to further the development of so-called bioelectronics or electroceuticals, which use electrical impulses rather than chemicals or biological molecules to treat disease. Ultimately, nanoscale implants could be developed to encourage insulin production, correct muscle imbalances or regulate food consumption, for example.

Full Story:

Related Summaries